Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study.
M Weintraub
https://pubmed.ncbi.nlm.nih.gov/1445528Completed
Phase 2
Age: 18Years - 60Years
All Genders
ID00000506
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2013-11-26
N/A
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine the long-term efficacy of the combination therapy of phentermine and fenfluramine in conjunction with diet, exercise, and behavior modification in the treatment of simple, moderate obesity.
CONDITIONS
Official Title
Cardiovascular System in Obesity: Effect of Treatment
Who Can Participate
Age: 18Years - 60Years
All Genders
Eligibility Criteria
You may qualify if you...
Men and women, ages 18 to 60. Body weight was 130 to 180 percent of ideal body weight.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
M Weintraub, P R Sundaresan, M Madan...
https://pubmed.ncbi.nlm.nih.gov/1587072Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
M Weintraub, P R Sundaresan, B Schuster...
https://pubmed.ncbi.nlm.nih.gov/1587073Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
M Weintraub, P R Sundaresan, B Schuster...
https://pubmed.ncbi.nlm.nih.gov/1587074Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
M Weintraub, P R Sundaresan, B Schuster...
https://pubmed.ncbi.nlm.nih.gov/1587075Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication.
M Weintraub, P R Sundaresan, B Schuster...
https://pubmed.ncbi.nlm.nih.gov/1587076Long-term weight control study. VI. Individual participant response patterns.
M Weintraub, P R Sundaresan, C Cox
https://pubmed.ncbi.nlm.nih.gov/1587077Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes.
M Weintraub, P R Sundaresan, B Schuster
https://pubmed.ncbi.nlm.nih.gov/1587078Long-term weight control study: conclusions.
M Weintraub
https://pubmed.ncbi.nlm.nih.gov/1587079